135 related articles for article (PubMed ID: 3410341)
21. Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.
Alitalo R; Andersson LC; Tapiovaara H; Sistonen L; Vaheri A; Stephens R
J Cell Physiol; 1989 Jul; 140(1):119-30. PubMed ID: 2500450
[TBL] [Abstract][Full Text] [Related]
22. Human hepatoma cell line plasminogen activator.
Levin EG; Fair DS; Loskutoff DJ
J Lab Clin Med; 1983 Oct; 102(4):500-8. PubMed ID: 6311924
[TBL] [Abstract][Full Text] [Related]
23. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
Meissauer A; Kramer MD; Schirrmacher V; Brunner G
Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956
[TBL] [Abstract][Full Text] [Related]
24. Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells.
Meissauer A; Kramer MD; Hofmann M; Erkell LJ; Jacob E; Schirrmacher V; Brunner G
Exp Cell Res; 1991 Feb; 192(2):453-9. PubMed ID: 1899072
[TBL] [Abstract][Full Text] [Related]
25. Demonstration of a functionally active tPA-like plasminogen activator in human platelets.
Wang DL; Pan YT; Wang JJ; Cheng CH; Liu CY
Thromb Haemost; 1994 Apr; 71(4):493-8. PubMed ID: 8052969
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of urokinase secretion from a human lymphoma cell line RC-K8 by dexamethasone without inducing plasminogen activator inhibitors.
Niiya K; Nsimba M; Hayashi T; Sakuragawa N
Thromb Res; 1992 Feb; 65(3):311-21. PubMed ID: 1631798
[TBL] [Abstract][Full Text] [Related]
27. Mouse trophoblastic cell lines: II--Relationship between invasive potential and proteases.
Sharma RK
In Vivo; 1998; 12(2):209-17. PubMed ID: 9627804
[TBL] [Abstract][Full Text] [Related]
28. Molecular characterization of plasminogen activators in human gingival crevicular fluid.
Brown JM; Watanabe K; Cohen RL; Chambers DA
Arch Oral Biol; 1995 Sep; 40(9):839-45. PubMed ID: 8651888
[TBL] [Abstract][Full Text] [Related]
29. Hydrocortisone regulates the dynamics of plasminogen activator and plasminogen activator inhibitor expression in cultured murine keratinocytes.
Bator JM; Cohen RL; Chambers DA
Exp Cell Res; 1998 Jul; 242(1):110-9. PubMed ID: 9665808
[TBL] [Abstract][Full Text] [Related]
30. [Plasminogen activators and plasminogen activator inhibitor type-1 in human endometrium].
Chen GA; Feng Q; Zhang LZ; Liu YX
Sheng Li Xue Bao; 1992 Oct; 44(5):502-9. PubMed ID: 1293766
[TBL] [Abstract][Full Text] [Related]
31. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion.
Ellerbroek SM; Hudson LG; Stack MS
Int J Cancer; 1998 Oct; 78(3):331-7. PubMed ID: 9766568
[TBL] [Abstract][Full Text] [Related]
32. Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells.
Miyagi E; Yasumitsu H; Hirahara F; Minaguchi H; Koshikawa N; Miyazaki K; Umeda M
Jpn J Cancer Res; 1995 Jun; 86(6):568-76. PubMed ID: 7622422
[TBL] [Abstract][Full Text] [Related]
33. Cellular and extracellular plasminogen activator and inhibitor in an experimental tumour.
Dong Q; Zhou MH; Subbarao V; Ts'ao CH
Br J Exp Pathol; 1988 Oct; 69(5):685-95. PubMed ID: 3143395
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Heidtmann HH; Hofmann M; Jacob E; Erbil C; Havemann K; Schwartz-Albiez R
Cancer Res; 1989 Dec; 49(24 Pt 1):6960-5. PubMed ID: 2555056
[TBL] [Abstract][Full Text] [Related]
35. Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines.
Yaginuma Y; Hayashi H; Kawai K; Kurakane T; Saitoh Y; Kitamura S; Sengoku K; Ishikawa M
Exp Cell Res; 1997 Jun; 233(2):233-9. PubMed ID: 9194486
[TBL] [Abstract][Full Text] [Related]
36. Vascular smooth muscle cells inhibit the plasminogen activators secreted by endothelial cells.
Laug WE
Thromb Haemost; 1985 Apr; 53(2):165-9. PubMed ID: 3927503
[TBL] [Abstract][Full Text] [Related]
37. Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Waghray A; Webber MM
Clin Cancer Res; 1995 Jul; 1(7):747-53. PubMed ID: 9816041
[TBL] [Abstract][Full Text] [Related]
38. PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: transcriptional regulation by TGF-beta 1.
Rougier JP; Guia S; Hagège J; Nguyen G; Ronco PM
Kidney Int; 1998 Jul; 54(1):87-98. PubMed ID: 9648067
[TBL] [Abstract][Full Text] [Related]
39. Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines.
Jones J; Lagasse LD; Karlan BY
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):421-6. PubMed ID: 7835782
[TBL] [Abstract][Full Text] [Related]
40. Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells.
Allan EH; Zeheb R; Gelehrter TD; Heaton JH; Fukumoto S; Yee JA; Martin TJ
J Cell Physiol; 1991 Oct; 149(1):34-43. PubMed ID: 1834680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]